The Burden of Coronavirus Disease 2019 and Its Complications in Patients With Atopic Dermatitis-A Nested Case-Control Study.
Journal
Dermatitis : contact, atopic, occupational, drug
ISSN: 2162-5220
Titre abrégé: Dermatitis
Pays: United States
ID NLM: 101207335
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
pubmed:
18
6
2021
medline:
29
10
2021
entrez:
17
6
2021
Statut:
ppublish
Résumé
The burden of coronavirus disease 2019 (COVID-19) among patients with atopic dermatitis (AD) is poorly understood. The aims of the study were to characterize a large cohort of COVID-19-positive adult patients with AD and to identify predictors of COVID-19-associated hospitalization and mortality. A population-based nested case-control study was performed. Multivariable logistic regression was used to evaluate odds ratios and 95% confidence intervals of predictors for COVID-19-associated hospitalization and mortality. Of 78,073 adult patients with AD, 3618 (4.6%) tested positive for COVID-19. Subclinical COVID-19 infection occurred in 3368 (93.1%) of COVID-19-positive patients, whereas 123 (3.4%), 46 (1.3%), 55 (1.5%), and 26 (0.7%) patients developed a mild, moderate, severe, and critical disease, respectively. Altogether, 250 patients (6.0%) were hospitalized, and 40 patients (1.1%) died because of COVID-19 complications. Coronavirus disease 2019-associated hospitalization was independently associated with the intake of extended courses of systemic corticosteroids (adjusted odds ratio, 1.96; 95% confidence interval, 1.23-3.14; P = 0.005). None of AD-related variables independently predicted COVID-19-associated mortality. The presence of comorbid metabolic syndrome, chronic obstructive pulmonary disease, chronic renal failure, and depression projected both COVID-19-associated hospitalization and mortality. Prolonged systemic corticosteroids during the pandemic are associated with increased odds of COVID-19-associated hospitalization and should be avoided in patients with AD.
Sections du résumé
BACKGROUND
BACKGROUND
The burden of coronavirus disease 2019 (COVID-19) among patients with atopic dermatitis (AD) is poorly understood.
OBJECTIVES
OBJECTIVE
The aims of the study were to characterize a large cohort of COVID-19-positive adult patients with AD and to identify predictors of COVID-19-associated hospitalization and mortality.
METHODS
METHODS
A population-based nested case-control study was performed. Multivariable logistic regression was used to evaluate odds ratios and 95% confidence intervals of predictors for COVID-19-associated hospitalization and mortality.
RESULTS
RESULTS
Of 78,073 adult patients with AD, 3618 (4.6%) tested positive for COVID-19. Subclinical COVID-19 infection occurred in 3368 (93.1%) of COVID-19-positive patients, whereas 123 (3.4%), 46 (1.3%), 55 (1.5%), and 26 (0.7%) patients developed a mild, moderate, severe, and critical disease, respectively. Altogether, 250 patients (6.0%) were hospitalized, and 40 patients (1.1%) died because of COVID-19 complications. Coronavirus disease 2019-associated hospitalization was independently associated with the intake of extended courses of systemic corticosteroids (adjusted odds ratio, 1.96; 95% confidence interval, 1.23-3.14; P = 0.005). None of AD-related variables independently predicted COVID-19-associated mortality. The presence of comorbid metabolic syndrome, chronic obstructive pulmonary disease, chronic renal failure, and depression projected both COVID-19-associated hospitalization and mortality.
CONCLUSIONS
CONCLUSIONS
Prolonged systemic corticosteroids during the pandemic are associated with increased odds of COVID-19-associated hospitalization and should be avoided in patients with AD.
Identifiants
pubmed: 34138775
doi: 10.1097/DER.0000000000000772
pii: 01206501-202110001-00010
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S45-S52Informations de copyright
Copyright © 2021 American Contact Dermatitis Society. All Rights Reserved.
Déclaration de conflit d'intérêts
The other authors have no funding or conflicts of interest to declare.
Références
Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 2020;20(2):124–127. doi:10.7861/clinmed.2019-coron.
doi: 10.7861/clinmed.2019-coron
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5.
doi: 10.1016/S0140-6736(20)30183-5
Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323(14):1406–1407. doi:10.1001/jama.2020.2565.
doi: 10.1001/jama.2020.2565
Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;27(5):1451–1454. doi:10.1038/s41418-020-0530-3.
doi: 10.1038/s41418-020-0530-3
Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity 2020;52(6):910–941. doi:10.1016/j.immuni.2020.05.002.
doi: 10.1016/j.immuni.2020.05.002
Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020;79(12):1544–1549. doi:10.1136/annrheumdis-2020-218296.
doi: 10.1136/annrheumdis-2020-218296
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician–reported registry. Ann Rheum Dis 2020;79(7):859–866. doi:10.1136/annrheumdis-2020-217871.
doi: 10.1136/annrheumdis-2020-217871
D'Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis 2020;79(9):1156–1162. doi:10.1136/annrheumdis-2020-217888.
doi: 10.1136/annrheumdis-2020-217888
Ansarin K, Taghizadieh A, Safiri S, et al. COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs. Ann Rheum Dis 2020;annrheumdis-2020-218737. doi:10.1136/annrheumdis-2020-218737.
doi: 10.1136/annrheumdis-2020-218737
Emmi G, Bettiol A, Mattioli I, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev 2020;19(7):102575. doi:10.1016/j.autrev.2020.102575.
doi: 10.1016/j.autrev.2020.102575
Liu M, Gao Y, Zhang Y, et al. The association between severe or dead COVID-19 and autoimmune diseases: a systematic review and meta-analysis. J Clean Prod 2020;81:e93–e95. doi:10.1016/j.jinf.2020.05.065.
doi: 10.1016/j.jinf.2020.05.065
Fredi M, Cavazzana I, Moschetti L, et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol 2020;2(9):e549–e556. doi:10.1016/S2665-9913(20)30169-7.
doi: 10.1016/S2665-9913(20)30169-7
Macaluso FS, Orlando A. COVID-19 in patients with inflammatory bowel disease: a systematic review of clinical data. Dig Liver Dis 2020;52(11):1222–1227. doi:10.1016/j.dld.2020.09.002.
doi: 10.1016/j.dld.2020.09.002
Stefanovic N, Flohr C, Irvine AD. The exposome in atopic dermatitis. Allergy 2020;75(1):63–74. doi:10.1111/all.13946.
doi: 10.1111/all.13946
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020;396(10247):345–360. doi:10.1016/S0140-6736(20)31286-1.
doi: 10.1016/S0140-6736(20)31286-1
Timberlake D, Narayanan D, Ogbogu P, et al. P350 effects of atopic disease on disease severity in COVID-19. Ann Allergy Asthma Immunol 2020;125(5):S43. doi:10.1016/j.anai.2020.08.147.
doi: 10.1016/j.anai.2020.08.147
Cohen AD, Dreiher J, Regev-Rosenberg S, et al. The quality indigators program in Clalit Health Services: the first decade [in Hebrew]. Harefuah 2010;149(4):204–9, 265.
Schoot TS, Kerckhoffs APM, Hilbrands LB, et al. Immunosuppressive drugs and COVID-19: a review. Front Pharmacol 2020;11:1333. doi:10.3389/fphar.2020.01333.
doi: 10.3389/fphar.2020.01333
Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J 2001;3(6):404–408. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11433630 . Accessed January 30, 2017.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–2497. doi:10.1001/jama.285.19.2486.
doi: 10.1001/jama.285.19.2486
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15(7):539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
Kridin K, Solomon A, Tzur-Bitan D, et al. Acne keloidalis nuchae and the metabolic syndrome: a population-based study. Am J Clin Dermatol 2020;21(5):733–739. doi:10.1007/s40257-020-00541-z.
doi: 10.1007/s40257-020-00541-z
Strom MA, Silverberg JI. Association between atopic dermatitis and extracutaneous infections in US adults. Br J Dermatol 2017;176(2):495–497. doi:10.1111/bjd.14708.
doi: 10.1111/bjd.14708
Langan SM, Abuabara K, Henrickson SE, et al. Increased risk of cutaneous and systemic infections in atopic dermatitis—a cohort study. J Invest Dermatol 2017;137(6):1375–1377. doi:10.1016/j.jid.2017.01.030.
doi: 10.1016/j.jid.2017.01.030
Silverberg JI, Silverberg NB. Childhood atopic dermatitis and warts are associated with increased risk of infection: a US population-based study. J Allergy Clin Immunol 2014;133(4):1041–1047. doi:10.1016/j.jaci.2013.08.012.
doi: 10.1016/j.jaci.2013.08.012
De Benedetto A, Agnihothri R, McGirt LY, et al. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 2009;129(1):14–30. doi:10.1038/jid.2008.259.
doi: 10.1038/jid.2008.259
Siegfried EC, Hebert AA. Diagnosis of atopic dermatitis: mimics, overlaps, and complications. J Clin Med 2015;4(5):884–917. doi:10.3390/jcm4050884.
doi: 10.3390/jcm4050884
Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012;130(6):1344–1354. doi:10.1016/j.jaci.2012.07.012.
doi: 10.1016/j.jaci.2012.07.012
Cure E, Kucuk A, Cumhur Cure M. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19). Rheumatol Int 2020;40(7):1177–1179. doi:10.1007/s00296-020-04603-7.
doi: 10.1007/s00296-020-04603-7
Safavi F, Nath A. Silencing of immune activation with methotrexate in patients with COVID-19. J Neurol Sci 2020;415:116942. doi:10.1016/j.jns.2020.116942.
doi: 10.1016/j.jns.2020.116942
Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020;159(2):481–491.e3. doi:10.1053/j.gastro.2020.05.032.
doi: 10.1053/j.gastro.2020.05.032
Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant 2020;20(7):1849–1858. doi:10.1111/ajt.15929.
doi: 10.1111/ajt.15929
Travi G, Rossotti R, Merli M, et al. Clinical outcome in solid organ transplant recipients with COVID-19: a single-center experience. Am J Transplant 2020;20(9):2628–2629. doi:10.1111/ajt.16069.
doi: 10.1111/ajt.16069
Mallapaty S. The coronavirus is most deadly if you are older and male—new data reveal the risks. Nature 2020;585(7823):16–17. doi:10.1038/d41586-020-02483-2.
doi: 10.1038/d41586-020-02483-2
Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York City. N Engl J Med 2020;382(24):2372–2374. doi:10.1056/nejmc2010419.
doi: 10.1056/nejmc2010419
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775.
doi: 10.1001/jama.2020.6775
Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46(5):846–848. doi:10.1007/s00134-020-05991-x.
doi: 10.1007/s00134-020-05991-x
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19–related death using OpenSAFELY. Nature 2020;584(7821):430–436. doi:10.1038/s41586-020-2521-4.
doi: 10.1038/s41586-020-2521-4
Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19–related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med 2020;8(11):1106–1120. doi:10.1016/S2213-2600(20)30415-X.
doi: 10.1016/S2213-2600(20)30415-X
Wang QQ, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry 2021;20(1):124–130. doi:10.1002/wps.20806.
doi: 10.1002/wps.20806
Ogedegbe G, Ravenell J, Adhikari S, et al. Assessment of racial/ethnic disparities in hospitalization and mortality in patients with COVID-19 in New York City. JAMA Netw Open 2020;3(12):e2026881. doi:10.1001/jamanetworkopen.2020.26881.
doi: 10.1001/jamanetworkopen.2020.26881